ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Incyte and Syndax Pharmaceuticals side by side

Their registered studies and the programs behind them, as ClinicalTrials.gov shows them and the companies' own pipelines name them. Counts, not rankings: the companies differ in size, so each number is shown beside its share of that company's own programs.

At a glance

Studies each sponsor leads, with the companies grouped under it. Every number opens the studies it counts.

IncyteSyndax Pharmaceuticals
studies on the registry31431
open to participants now344
phase 3 studies under way241
reach primary completion within a year221
programswith a study of their own in two years171

Pipeline by phase

Each program once, at the furthest phase its own studies reached. The bar is the share of that company's programs, so a small company and a large one read on the same scale.

Furthest phaseIncyteSyndax Pharmaceuticals
Phase 129%00%
Phase 2

Incyte: 3 of its 17 programs at phase 2

  1. INCB057643phase 2
  2. INCA000585phase 2
  3. DGK Alpha/Zeta Inhibitor INCB177054phase 2
18%
00%
Phase 347%

Syndax Pharmaceuticals: 1 of its 1 programs at phase 3

  1. revumenibphase 3
100%
Approved, new studies

Incyte: 1 of its 17 programs at approved, new studies

  1. ruxolitinibapproved, new study
6%
00%

Readouts ahead

Programs whose next study reaches primary completion in each month, by the sponsor's own estimate. A ring marks a month with a phase 3 readout.

Nov ’26DecJan ’27FebMarAprMayJunJulAugSepOct
Incyte8 readouts · 0 phase 3

Incyte, Nov ’26: 1 program whose next study reaches primary completion

  1. povorcitinibphase 3 · Nov 20 · NCT05851443

Incyte, Dec ’26: 1 program whose next study reaches primary completion

  1. ruxolitinibapproved, new study · Dec 9 · NCT07049575

Incyte, Jan ’27: 3 programs whose next study reaches primary completion

  1. KRAS G12D Inhibitor INCB161734phase 3 · Jan 1 · NCT06179160
  2. CDK2 Inhibitor INCB123667phase 3 · Jan 4 · NCT07559396
  3. axatilimabphase 3 · Jan 6 · NCT06843408
·

Incyte, Mar ’27: 1 program whose next study reaches primary completion

  1. KRAS G12D Inhibitor INCB186748phase 1 · Mar 27 · NCT06818812

Incyte, Apr ’27: 1 program whose next study reaches primary completion

  1. INCB057643phase 2 · Apr 30 · NCT04279847
····

Incyte, Sep ’27: 1 program whose next study reaches primary completion

  1. INCA000585phase 2 · Sep 23 · NCT07104565
·
Syndax Pharmaceuticals1 readouts · 0 phase 3···

Syndax Pharmaceuticals, Feb ’27: 1 program whose next study reaches primary completion

  1. revumenibphase 3 · Feb 0 · NCT06226571
········
size: programs that monthincludes phase 3Dates are estimates the sponsors file and often move.

Changed in the last 90 days

Since Aug 22, 2026: programs whose first study was registered, programs that reached a new phase, studies stopped, and primary completions moved later (a month or more in phase 3, three otherwise). Stops and dates are read from the registry’s changes, kept since Sep 25, 2026.

Incyte

New programs 0

None

Reached a new phase 0

None

Study stopped 0

None

Primary completion later 0

None

Syndax Pharmaceuticals

New programs 0

None

Reached a new phase 0

None

Study stopped 0

None

Primary completion later 0

None

Where they overlap

Conditions where at least two of them have programs: 2 in all. A program counts in each condition its studies name most.

ConditionIncyteSyndax Pharmaceuticals
Colorectal Neoplasmsboth · compare here

Syndax Pharmaceuticals in Colorectal Neoplasms: 1 program

  1. revumenibphase 3

Their studies: Syndax Pharmaceuticals’ studies of Colorectal Neoplasms in search

Hematologic Neoplasmsboth · compare here

Incyte in Hematologic Neoplasms: 1 program

  1. Anti-CD70/CD3 Bispecific Antibody INCA036873phase 1

Their studies: Incyte’s studies of Hematologic Neoplasms in search

Syndax Pharmaceuticals in Hematologic Neoplasms: 1 program

  1. revumenibphase 3

Their studies: Syndax Pharmaceuticals’ studies of Hematologic Neoplasms in search

Same targetBetaPro · free during the beta

Programs that act on the same gene, from the company’s own words, a judged reading of NCIt, ChEMBL or the studies, or a rule. A reading by rule is marked rule.

No gene two of them both target, among the programs whose target is known.

A target, or a pathogen for a vaccine, known for: Incyte 9 of 17 · Syndax Pharmaceuticals 1 of 1 programs (10 of them by rule). Most early programs are named only by a code and their companies do not say what they act on, so this list is short and grows as targets are read.

What this can't show

  • Only what ClinicalTrials.gov holds: programs run only in other registries are missing.
  • Grouping is ours: subsidiaries and acquisitions counted under the parent, each dated and sourced on the sponsor page.
  • Readout dates are the sponsors’ estimates, not results.
  • A program is a drug as the registry names it: a code its company has not tied to a name counts on its own until it is read, and a study run under a partner’s name counts for the partner.
  • “Same target” covers only the programs whose target is known, from the company’s words, a judged reading or a rule; most early programs say nothing of it.